Patents by Inventor Thomas C. Malone

Thomas C. Malone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors
    Patent number: 9657005
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: May 23, 2017
    Assignee: ALLERGAN, INC.
    Inventors: Xialing Guo, Zhen Zhu, Thomas C. Malone, Julie Wurster
  • Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
    Patent number: 9650366
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: May 16, 2017
    Assignee: ALLERGAN, INC.
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang, Sandhya Rao, Rong Yang
  • PYRIDYL BENZOTHIOPHENES AS KINASE INHIBITORS
    Publication number: 20170107210
    Abstract: This invention is directed to compounds, which are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.
    Type: Application
    Filed: May 23, 2016
    Publication date: April 20, 2017
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang
  • HETEROCYCLE-SUBSTITUTED PYRIDYL BENZOTHIOPHENES AS KINASE INHIBITORS
    Publication number: 20170096419
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
    Type: Application
    Filed: May 11, 2016
    Publication date: April 6, 2017
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang, Sandhya Rao, Rong Yang
  • Substituted nicotinamide derivatives as kinase inhibitors
    Patent number: 9567324
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: February 14, 2017
    Assignee: ALLERGAN, INC.
    Inventors: Sougato Boral, Shimiao Wang, Thomas C. Malone, Julie Wurster, Jie Shen, Michael Robinson
  • 4-pregenen-11?-17-21-triol-3,20-dione derivatives
    Patent number: 9433631
    Abstract: The present invention relates to novel 4-pregenen-11?-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or mineralocorticoid receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid receptor modulation.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: September 6, 2016
    Assignee: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Alissar Nehme, Thomas C. Malone
  • Indole-3-carboxamides as kinase inhibitors
    Patent number: 9403803
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: August 2, 2016
    Assignee: Allergan, Inc.
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang
  • BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS
    Publication number: 20160199297
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol.
    Type: Application
    Filed: January 11, 2016
    Publication date: July 14, 2016
    Inventors: Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
  • Substituted 1,2,3,4-tetrahydropyrido[3,4-E] pyrrolo[1,2-A]pyrimidines as kinase
    Patent number: 9388181
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: July 12, 2016
    Assignee: Allergan, Inc.
    Inventors: Clarence Eugene Hull, III, Thomas C. Malone
  • Method of treating conditiions with kinase inhibitors
    Patent number: 9388176
    Abstract: The present invention relates to a method of treating ophthalmic diseases and conditions, e.g. diabetic retinopathy, age-related macular degeneration, retinopathy of prematurity, etc., in a subject comprising administering to said subject a therapeutically effective amount of at least one compound of formula I or a prodrug, pharmaceutically acceptable salt, racemic mixtures or enantiomers of said compound. The compounds of formula I are capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: July 12, 2016
    Assignee: ALLERGAN, INC.
    Inventors: Clarence E. Hull, III, Thomas C. Malone
  • Pyridyl benzothiophenes as kinase inhibitors
    Patent number: 9371314
    Abstract: This invention is directed to compounds, which are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: June 21, 2016
    Assignee: Allergan, Inc.
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang
  • Kinase inhibitors
    Patent number: 9365575
    Abstract: The present invention relates to compounds of Formula I or a pharmaceutically acceptable salt thereof, wherein variables R, Ar, X, and Ar1 and n are as defined herein. The compounds are capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: June 14, 2016
    Assignee: Allergan, Inc.
    Inventors: Thomas C. Malone, Julie A. Wurster, Clarence Eugene Hull, III
  • Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
    Patent number: 9359336
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: June 7, 2016
    Assignee: Allergan, Inc.
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang, Sandhya Rao, Rong Yang
  • Indole-1-carboxamides as kinase inhibitors
    Patent number: 9353093
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: May 31, 2016
    Assignee: Allergan, Inc.
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang
  • Kinase inhibitors
    Patent number: 9321766
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: April 26, 2016
    Assignee: Allergan, Inc.
    Inventors: Julie Wurster, Richard Yee, Clarence Eugene Hull, III, Thomas C. Malone
  • Kinase inhibitors
    Patent number: 9321721
    Abstract: The present invention relates to compounds of formula I or a pharmaceutically acceptable salts thereof; wherein the variables R1—R5, Ar1, and X are as defined herein. The compounds are capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: April 26, 2016
    Assignee: Allergan, Inc.
    Inventors: Thomas C. Malone, C. Eugene Hull, III
  • Heterocycle-substituted Pyridyl Benzothiophenes as Kinase Inhibitors
    Publication number: 20160102081
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
    Type: Application
    Filed: October 9, 2014
    Publication date: April 14, 2016
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang, Sandhya Rao, Rong Yang
  • PYRIDYL BENZOTHIOPHENES AS KINASE INHIBITORS
    Publication number: 20160102080
    Abstract: This invention is directed to compounds, which are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.
    Type: Application
    Filed: October 9, 2014
    Publication date: April 14, 2016
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang
  • Indole-3-Carboxamides as Kinase Inhibitors
    Publication number: 20160102077
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
    Type: Application
    Filed: October 8, 2014
    Publication date: April 14, 2016
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang
  • PIPERIDYLPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASE INHIBITORS AND OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2
    Publication number: 20160102088
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein X, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. The compounds of Formula I are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.
    Type: Application
    Filed: October 10, 2014
    Publication date: April 14, 2016
    Inventors: Julie A. Wurster, Thomas C. Malone, Clarence Eugene Hull, III, Sandhya Rao, Rong Yang, Richard Yee